Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Marsoni

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Breast Cancer Research and Treatment|April 30, 2010
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancerMaurizia Mello-Grand, Vijay Singh, Chiara Ghimenti, et al.
Clinical Colorectal Cancer|April 15, 2019
A Genomic Analysis Workflow for Colorectal Cancer Precision OncologyGiorgio Corti, Alice Bartolini, Giovanni Crisafulli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
International Journal of Cancer|September 3, 2020
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapyValentina Giannini, Samanta Rosati, Arianna Defeudis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation studyFederico Rojo, Elías Gracias, Nadia Villena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomasGiorgia Migliardi, Francesco Sassi, Davide Torti, et al.
NPJ Precision Oncology|October 14, 2024
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionGiorgio Corti, Kristi Buzo, Enrico Berrino, et al.
The Oncologist|March 30, 2026
Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomasEnrico Berrino, Sara Erika Bellomo, Maria Costanza Aquilano, et al.
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
Cancer Discovery|May 13, 2026
Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive ProgramChiara Maria Cattaneo, Sharon Scardellato, Gianluca Mauri, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Breast Cancer Research and Treatment|April 30, 2010
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancerMaurizia Mello-Grand, Vijay Singh, Chiara Ghimenti, et al.
Clinical Colorectal Cancer|April 15, 2019
A Genomic Analysis Workflow for Colorectal Cancer Precision OncologyGiorgio Corti, Alice Bartolini, Giovanni Crisafulli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
International Journal of Cancer|September 3, 2020
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapyValentina Giannini, Samanta Rosati, Arianna Defeudis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation studyFederico Rojo, Elías Gracias, Nadia Villena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomasGiorgia Migliardi, Francesco Sassi, Davide Torti, et al.
NPJ Precision Oncology|October 14, 2024
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionGiorgio Corti, Kristi Buzo, Enrico Berrino, et al.
The Oncologist|March 30, 2026
Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomasEnrico Berrino, Sara Erika Bellomo, Maria Costanza Aquilano, et al.
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
Cancer Discovery|May 13, 2026
Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive ProgramChiara Maria Cattaneo, Sharon Scardellato, Gianluca Mauri, et al.
Pageof 9